Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1- infected patients under antiretroviral treatment

Current Pharmaceutical Design

Volumn 16, Issue 30, 2010, Pages 3372-3378

  Giralt, Marta ^a   Díaz Delfín, Julieta ^a   Gallego Escuredo, José M ^a   Villarroya, Joan ^a,b   Domingo, Pere ^b   Villarroya, Francesc ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Adipose tissue; Fatty acids; HIV; Lipodystrophy; Lipotoxicity

Indexed keywords

1 ACYLGLYCEROPHOSPHATE ACYLTRANSFERASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACIPIMOX; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAVEOLIN 1; CELL PROTEIN; EFAVIRENZ; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; LAMININ; LEPTIN; LIPOPROTEIN LIPASE; NEVIRAPINE; SEIPIN; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TESAMORELIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; ZIDOVUDINE;

ADIPOCYTE; ADIPOGENESIS; APOPTOSIS; ARTICLE; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CLINICAL TRIAL; CONGENITAL GENERALIZED LIPODYSTROPHY; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FAMILIAL PARTIAL LIPODYSTROPHY; GROWTH HORMONE RELEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID STORAGE; LIPOLYSIS; LIPOTOXICITY; LIVER; METABOLIC SYNDROME X; MITOCHONDRIAL TOXICITY; MUSCLE; OBESITY; PANCREAS; PATHOGENESIS; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TISSUE EXPANSION; TOXICITY; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; DRUG DESIGN; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; METABOLISM; METHODOLOGY; PATHOLOGY; REVIEW;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; DRUG DESIGN; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INFLAMMATION; METABOLIC SYNDROME X;

EID: 78649823095     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563527     Document Type: Article

References (82)

1. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010; 1801: 209-14.
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
3. Villarroya F, Domingo P, Giralt M, Lipodystrophy in HIV 1- infected patients: lessons for obesity research. Int J Obes (Lond) 2007; 31: 1763-76.
4. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective. Biochim Biophys Acta 2010; 1801: 338-49.
5. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004; 89: 2569-75.
6. Soverini V, Moscatiello S, Villanova N, Ragni E, Di Domizio S, Marchesini G. Metabolic syndrome and insulin resistance in subjects with morbid obesity. Obes Surg 2010; 20(3): 295-301.
7. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350: 1220-34.
8. Agarwal AK, Arioglu E, de Almeida S, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002; 31: 21-3.
9. Magre J, Delepine M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001; 28: 365-70.
10. Kim CA, Delepine M, Boutet E, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab 2008; 93: 1129-34.
11. Haque WA, Shimomura I, Matsuzawa Y, et al. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002; 87: 2395-8.
12. Hegele RA, Joy TR, Al-Attar SA, et al. Lipodystrophies: windows on adipose biology and metabolism. J Lipid Res 2007; 48: 1433-44.
13. Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta 2009; 1791: 507-13.
14. Savage DB. Mouse models of inherited lipodystrophy. Dis Model Mech 2009; 2: 554-62.
15. Cortes VA, Curtis DE, Sukumaran S, et al. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab 2009; 9: 165-76.
16. Cutler DA, Sullivan T, Marcus-Samuels B, et al. Characterization of adiposity and metabolism in Lmna-deficient mice. Biochem Biophys Res Commun 2002; 291: 522-7.
17. Wojtanik KM, Edgemon K, Viswanadha S, et al. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan's partial lipodystrophy mutation. J Lipid Res 2009; 50: 1068-79.
18. Reitman ML. Metabolic lessons from genetically lean mice. Annu Rev Nutr 2002; 22: 459-82.
19. Reue K, Phan J. Metabolic consequences of lipodystrophy in mouse models. Curr Opin Clin Nutr Metab Care 2006; 9: 436-41.
20. Asterholm IW, Halberg N, Scherer PE. Mouse models of lipodystrophy key reagents for the understanding of the metabolic syndrome. Drug Discov Today Dis Models 2007; 4: 17-24.
21. Wang ND, Finegold MJ, Bradley A, et al. Impaired energy homeostasis in C/EBP alpha knockout mice. Science 1995; 269: 1108-12.
22. Carmona MC, Iglesias R, Obregón MJ, et al. Mitochondrial biogenesis and thyroid status maturation in brown fat require CCAAT/enhancer-binding protein alpha. J Biol Chem 2002; 277: 21489-98.
23. Linhart HG, Ishimura-Oka K, Demayo F, et al. C/EBPalpha is required for differentiation of white, but not brown, adipose tissue. Proc Natl Acad Sci USA 2001; 98: 12532-7.
24. Gray SL, Dalla Nora E, Vidal-Puig AJ. Mouse models of PPARgamma deficiency: dissecting PPAR-gamma's role in metabolic homoeostasis. Biochem Soc Trans 2005; 33: 1053-8.
25. Duan SZ, Ivashchenko CY, Whitesall SE, et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgammadeficient mice rescued from embryonic lethality. J Clin Invest 2007; 117: 812-22.
26. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates highfat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597-609.
27. Koutnikova H, Cock TA, Watanabe M, et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci USA 2003; 100: 14457-62.
28. Gray SL, Nora ED, Grosse J, et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 2006; 55: 2669-77.
29. Ross SR, Graves RA, Spiegelman BM. Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity. Genes Dev 1993; 7: 1318-24.
30. Pajvani UB, Trujillo ME, Combs TP, et al. Fat apoptosis through targeted activation of caspase 8, a new mouse model of inducible and reversible lipoatrophy. Nat Med 2005; 11: 797-803.
31. Moitra J, Mason MM, Olive M, et al. Life without whitefat: a transgenic mouse. Genes Dev 1998; 12: 3168-81.
32. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271-8.
33. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-94.
34. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-6.
35. Colombo C., Cutson JJ, Yamauchi T, Vinson C, Kadowaki T, Gavrilova O, Reitman ML. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002; 51: 2727-33
36. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-8.
37. Boyd MA, Carr A, Ruxrungtham K, et al. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis 2006; 194: 642-50.
38. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005; 26: 88-93.
39. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002; 51: 1143-7.
40. Van Vonderen MG, Blümer RM, Hassink EA, et al. Insulin sensitivity in multiple pathways is differently affected during zidovudine/ lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 53: 186-93
41. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18: 2127-36.
42. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106
43. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-18.
44. Negredo E, Paredes R, Bonjoch A, et al. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up. Antivir Ther 1999; 3: 23-8.
45. Gonzalez-Tome MI, Amador JT, Peña MJ, Gomez ML, Conejo PR, Fontelos PM. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. BMC Infect Dis 2008; 8: 144.
46. Fisac C, Fumero E. Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19: 917-25.
47. Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapynaive patients infected with HIV-1. PLoS Med 2004; 1: e19.
48. El Hadri M, Glorian C, Monsempes MN, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes, J Biol Chem 2004; 279: 15130-4
49. Flint OP, Noor MA, Hruz PW, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 2009; 37: 65-77
50. Rudich A, Vanounou S, Riesenberg K, et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001; 50: 1425-31.
51. Parker RA, Flint OP, Mulvey R, et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005; 67: 1909-19.
52. Djedaini M, Peraldi P, Drici MD, et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun 2009; 386: 96-100.
53. Wu X, Sun L, Zha W, et al. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 2010; 138: 197-209.
54. Peck MD, Mantero-Atienza E, Miguez-Burbano MJ, et al. The esterified plasma fatty acid profile is altered in early HIV-1 infection. Lipids 1993; 28: 593-7.
55. Van der Valk M, Reiss P, Van Leth FC, et al. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J Clin Endocrinol Metab 2002; 87: 5066-71.
56. Giralt M, Domingo P, Villarroya F. HIV-1 infection and the PPARgamma-dependent control of adipose tissue physiology. PPAR Res 2009; 2009: 607902
57. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191: 1686-96
58. Bastard P, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-31.
59. Giralt M, Domingo P, Guallar JP et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAARTassociated lipodystrophy. Antivir Ther 2006; 11: 729-40.
60. Hadigan C, Rabe J, Meininger G, Aliabadi N, Breu J, Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 2003, 77: 490-4
61. Hadigan C, Liebau J, Torriani M, et al. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab 2006; 91: 4438-44.
62. Lindegaard B, Frøsig C, Petersen AM, et al. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy. Diabetes 2007; 56: 2070-7.
63. Guo W, Wong S, Pudney J, et al. Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir. Arterioscler Thromb Vasc Biol 2009; 29: 2028-32.
64. den Boer MA, Berbée JF, Reiss P, et al. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol 2006; 26: 124-9.
65. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-48.
66. Rodríguez de la Concepción ML, Yubero P, Domingo JC, et al. Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. Antivir Ther 2005; 10: 515-26.
67. Guallar JP, Gallego-Escuredo JM, Domingo JC, et al. Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. AIDS 2008; 22: 575-84
68. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18
69. Pirmohamed M. Clinical management of HIV-associated lipodystrophy. Curr Opin Lipidol 2009; 20: 309-14.
70. Sutinen J. The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients. PPAR Res 2009; 2009: 373524
71. Park JY, Javor ED, Cochran EK, et al. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism 2007; 56: 508-16.
72. Guettier JM, Park JY, Cochran EK, et al. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clin Endocrinol (Oxf) 2008; 68: 547-54.
73. Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003; 36: 795-802.
74. Mantzoros CS. Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab 2009; 94: 1089-91.
75. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86: 504-10.
76. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999; 13: 2099-103
77. Lo JC, Mulligan K, Noor MA, et al. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis 2004; 39: 732-5.
78. D'Amico S, Shi J, Sekhar RV, et al. Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr 2006; 84: 204-11.
79. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357: 2359-70.
80. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11(14): 1805-43.
81. Barbaro G. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des 2007; 13(21): 2208-13.
82. Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006; 12(9): 1075-90.